Parasite clearance data from 18,699 patients with falciparum malaria treated with an artemisinin derivative in areas of low ( ), moderate ( ), and high ( ) levels of malaria transmission across n p 14,539 n p 2077 n p 2083 the world were analyzed to determine the factors that affect clearance rates and identify a simple in vivo screening measure for artemisinin resistance. The main factor affecting parasite clearance time was parasite density on admission. Clearance rates were faster in high-transmission settings and with more effective partner drugs in artemisinin-based combination treatments (ACTs). The result of the malaria blood smear on day 3 (72 h) was a good predictor of subsequent treatment failure and provides a simple screening measure for artemisinin resistance. Artemisinin resistance is highly unlikely if the proportion of patients with parasite densities of !100,000 parasites/mL given the currently recommended 3-day ACT who have a positive smear result on day 3 is !3%; that is, for n patients the observed number with a positive smear result on day 3 does not exceed .
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Artemisinin-based combination treatments (ACTs) are recommended for falciparum malaria throughout the tropical world [1] . Stable resistance to artemisinin and Cambodian border [3] [4] [5] [6] [7] [8] . From the same geographic area, there is now evidence of reduced susceptibility to artemisinin derivatives and ACTs with prolonged parasite clearance times and day 42 failure rates up to 20% for artesunate-mefloquine and day 28 failure rates between 13% to 29% for artemether-lumefantrine [2, [9] [10] [11] [12] [13] [14] . If artemisinin resistance were to spread as resistance to chloroquine and sulfadoxine-pyrimethamine has spread before, it would threaten malaria control and seriously challenge current initiatives to eliminate malaria. At present, there is no validated molecular marker or in vitro test of artemisinin resistance. We have examined the largest available database of antimalarial clinical trials [15] and detailed studies of patients with hyperparasitemia to characterize parasite clearance after treatment with artemisinin derivatives. The objective was to identify a simple indicator that could be used to screen for artemisinin resistance during standard in vivo efficacy studies and surveillance programs.
METHODS

Background
In 2002, a group of investigators conducting antimalarial drug studies decided to pool their data on therapeutic responses in uncomplicated falciparum malaria obtained in diverse geographic locations with differing malaria transmission intensities [15] . The objective was to characterize the efficacy of different antimalarial drug treatments and to determine the effects of covariates (such as transmission intensity, age, and parasite density) on therapeutic responses. This will now be incorporated into the Worldwide Antimalarial Resistance Network, or WWARN [16] . In total, data on 31,708 individual patients from 85 prospective studies conducted in 25 countries were pooled and analyzed. Of these patients, 17,546 (55%) received an artemisinin derivative, either alone or in combination with a more slowly eliminated antimalarial drug. Many clinical trials excluded patients with high parasite densities. Because the decline in parasite density after antimalarial treatment is exponential (a first-order process) [17] [18] [19] , the parasite clearance time is directly proportional to the logarithm of the initial parasite count; thus, excluding hyperparasitemia creates a potential confounder. To investigate this further, a large data set for patients studied on the northwestern border of Thailand with parasitemia levels of 14% (termed hyperparasitemia in this article) was also studied. The overall objective of this analysis was to provide a statistical basis for prospectively characterizing in vivo resistance to artemisinin and its derivatives.
Clinical and Parasitological Data
Two sources of data were used for this analysis.
World [15] . Parasite densities were available at enrollment (day 0) and then on days 1 (ie, ∼24 h after the start of treatment), 2, 3, and 7, although the exact times of measurement were usually not recorded.
Shoklo Malaria Research Unit hyperparasitemia database. Data from patients in the Shoklo Malaria Research Unit (SMRU) hyperparasitemia database who were admitted with levels of parasitemia of 14% between January 2001 and June 2008 ( ) were analyzed. Parasite counts were measured n p 1687 every 6 h until clearance. Exact blood sampling times were recorded.
Blood smears were stained with Giemsa stain, and parasites were counted on the thin or thick smear against 1000 red blood cells or 1000, 500, or 200 white blood cells. The number of parasites per microliter was calculated using measured individual hematocrit values for thin smears or by assuming a white blood cell count of 8000 cells/mL for thick smears. Other data collected included demographic characteristics (age, weight, sex, etc), treatment and doses given, and information on symptoms, signs, temperature, gametocytemia, and hematological and biochemical data. Recurrence of parasitemia during the follow-up period, together with polymerase chain reaction (PCR) genotyping results, were recorded for patients in the TDR-WT database but were not routinely recorded for patients in the SMRU hyperparasitemia database.
Statistical Analysis
Since areas of different transmission intensity differ with respect to patient populations, antimalarial treatment, and length of follow-up, all analyses (unless specified) were performed separately for each level of transmission intensity. This stratification was defined a priori.
Parasite positivity rates (PPRs), or the proportions of patients with parasitemia, were recorded on days 1, 2, and 3. Overall PPRs were calculated as a weighted average of study treatment arm-specific proportions. Confidence intervals (CIs) were estimated using a method for clustered data described by Fleiss et al [20] . The PPRs were compared between groups of studies (determined by region or treatment) by the F test, using grouped logistic regression. CIs for ordinary proportions were calculated using the Wilson method [21] .
Associations between positive parasite counts on day 2 or 3 and subsequent recrudescence of infection were assessed by comparison of the cumulative recrudescence proportions, es- timated using the Kaplan-Meier method. Patients with missing PCR results were excluded, and patients who were lost to follow-up or who had new infections during follow-up were censored at the last follow-up visit. Studies without PCR genotyping were excluded from this analysis.
The terminal relationship between log-transformed parasite density and time was assumed to be linear [17] . Therefore, if the lower limit of microscopic detection is 50 parasites/mL, P is the admission parasite density, k is the first-order clearance rate constant, and T is the time to parasite clearance then . As a consequence, the admission par-T p (log P Ϫ log 50)/k asite density (P) affects the time of clearance and the probability of having a positive count at any specified time. Parasite clearance rate constants (k) for artesunate alone were estimated from patients in the SMRU hyperparasitemia database, who received artesunate only during the first 48 h, analyzing the slope of the log parasite count-time relationship for each patient from linear regression fits, using all measurements taken up to 48 h.
The effects of parasite count and other covariates on the probability of parasite clearance by day 3 were investigated for all patients receiving antimalarial treatments currently recommended by the WHO by logistic regression and were expressed as odds ratios (ORs) and 95% CIs. Random-effects models were used to account for the heterogeneous nature of the data and were fitted separately within each transmission intensity stratum. A pooled model was also fitted, using data from patients who received treatments that were common in at least 2 areas of different endemicity. Because recent evidence has indicated that parasite clearance times have been increasing on the western border of Thailand since 2001 [22] , the data from SMRU patients were analyzed separately from the other data sets.
In all analyses, patients who received a blood transfusion were excluded. No patients in the TDR-WT database received blood, whereas 97 patients with hyperparasitemia in the SMRU database (6% of 1687 patients in the SMRU hyperparasitemia database and 5% of all 2068 patients with hyperparasitemia) received transfusions. In the TDR-WT database, patients who received rescue treatment after experiencing early treatment failure were censored at the time of retreatment. In the SMRU hyperparasitemia database, parasite counts were also available after the rescue treatment. Because these patients had the longest initial parasites clearance times, they were included in the analysis, but the characteristics of parasite clearance (PPR and clearance rate) are contrasted with those of other patients.
RESULTS
In total, 18,699 patients treated with an artemisinin derivative were included in this analysis: (1) 8984 with uncomplicated malaria studied by the SMRU and included in the TDR-WT database; (2) 8027 from studies in other countries included in the TDR-WT database (3867 in low-transmission areas, 2077 in moderate-transmission areas, and 2083 in high-transmission areas); and (3) 1590 with hyperparasitemia studied by the SMRU (Table 1 ). The artemisinin derivative was given either 
Parasite Positivity Rates
On admission, the median parasite density was par- 4 1.2 ϫ 10 asites/mL (range, limit of detection to parasites/mL) 6 1.8 ϫ 10 among patients with uncomplicated malaria and was 5 2.7 ϫ 10 parasites/mL (range, to parasites/mL) among 5 6 1.9 ϫ 10 2.3 ϫ 10 patients with hyperparasitemia in the SMRU database (Table 1) . Parasite clearance times were significantly faster in patients with lower initial densities ( ). Parasitological responses to ar-P ! .001 temisinins, either alone or in combination, were slightly faster in high-transmission areas than elsewhere (Table 3) , but the differences between areas were not statistically significant. Excluding the SMRU studies, estimated PPRs on day 3 among all patients with uncomplicated malaria treated with artemisinin derivatives were 2.0% (95% CI, 0.6%-3.3%) in the high-transmission areas, 3.4% (95% CI, 0%-7.2%) in the moderate-transmission areas, and 2.9% (95% CI, 2.0%-3.9%) in the low-transmission areas ( ). For patients with hyperparasitemia ( ), the P p .364 n p 1583 PPR at 72 h was much higher-24% (95% CI, 22%-26%), decreasing to 5.5% (95% CI, 4.5%-6.8%) at 96 h. Of these patients, 66 received rescue treatment; their PPRs at 72 h (44% [95% CI, 33%-57%]) and at 96 h (13% [95% CI, 7%-24%]) were significantly higher than those for the other patients ( and P ! .001 , respectively). P p .006 Figure 2 . Relationship between enrollment parasite density and the proportion of patients with parasitemia on day 3 after the start of treatment with artemisinin derivatives, estimated using logistic regression with random effects for study site. The outer dashed and continuous lines represent 95% and 99% confidence intervals.
Predictors of Subsequent Recrudescence
The presence of parasites on day 3 (ie, ∼72 h after the start of treatment) emerged as the best determinant of subsequent recrudescence ( Figure 1) . In low-and moderate-transmission areas, the risk of recrudescent parasitemia was !5% in patients who cleared parasitemia by day 3. In contrast, among patients with parasitemia on day 3 this risk was 12%, 34%, and 16% in low-transmission areas, in moderate-transmission areas, and among the SMRU patients with uncomplicated malaria, respectively ( for all) ( Figure 1C ). In the high-transmis-P ! .001 sion areas, rates of recrudescence for both groups of patients were higher, but patients with detectable parasitemia on day 3 still had double the risk of recrudescent parasitemia compared with patients who were parasite negative on day 3 ( ). P p .118 The positive predictive value of parasite positivity on day 3 in predicting treatment failure is equal to the estimated risks of failure described above, and the negative predictive value is equal to risk of success in patients with a negative count on day 3 (97.5%, 95%, 90%, and 95%, respectively) ( Figure 1C ).
Parasite Clearance Rate Constants
The parasite clearance rate constant (k) could be estimated in 1570 individuals in the SMRU hyperparasitemia database; in 95% ( ), the linear regression fit was satisfactory (men p 1495 dian ). Among these patients, the median slope was 2 R p 0.92 estimated to be 0.097 per 1 h (range, 0.015-0.333 per 1 h) and had a symmetrical distribution (mean, 0.101; standard deviation, 0.032). Parasite clearance rate constants did not correlate with initial parasitemia ( ; ). These slope values r p .010 P p .71 s correspond to a median half-life of 3.1 h (range, 0.9-19.4 h) or parasite reduction rates ranging from 1.25 to 2.15/h. Parasite clearance among the 63 patients who received rescue treatment was significantly slower than that among the remainder, with a median half-life of 3.6 h (range, 2.4-11.8 h) and a median parasite reduction rate of 1.21/h (range, 1.06-1.33/h) ( ) . P ! .001
Analysis of Covariates Affecting Parasite Clearance
The OR for failure to clear parasitemia by day 3 per 10-fold increase in admission parasite density was 3.862 (95% CI, (Figure 2) .
Data on spleen examination were available for 11,340 patients (8699 SMRU patients and 448, 1145, and 1048 patients in the low-, moderate-, and high-transmission areas); there was no difference in parasite clearance rates among patients with or without splenomegaly in each area. No other patient or disease characteristics (age, sex, presence of gametocytes on enrollment) were associated independently with the probability of parasitemia persisting to day 3. The heterogeneity between studies within each area was statistically significant (P ! .001 for all). The duration of artemisinin treatment (1 or у3 days) and the partner drug administered were important determinants of parasite clearance rates. Overall, 5.8% (108/1849; 95% CI, 1.6%-10.0%) of patients who received artemisinin treatment for 1 day had parasitemia on day 3, compared with 1.4% (187/13,097; 95% CI, 1.0%-1.8%) of patients treated with artemisinin for у3 days ( ), although the rates varied be-P ! .001 tween partner drugs (Table 4) .
Effects of Partner Drugs
Low-transmission areas. PPRs obtained for artemether-lumefantrine, mefloquine-artemether/artesunate or dihydroartemisinin-piperaquine, after adjustment for initial parasite density, were each significantly lower than those for treatments with artesunate combined with the less efficacious partners amodiaquine or chloroquine (overall OR, 0.148 [95% CI, 0.057-0.387];
). Within these 2 groups of treatments, P ! .001 the PPRs were not significantly different. PPRs for artesunate and sulfadoxine-pyrimethamine were higher than for mefloquine-artemether/artesunate (OR, 0.117 [95% CI, 0.019-0.716]) but were not significantly different from other treatments. After adjustment for treatments and parasite densities, there was no heterogeneity between study sites ( ). P p .447 Among SMRU patients, there were no significant differences between PPRs with different 3-day treatments (test for heterogeneity between studies, ). P ! .001 Moderate-transmission areas. After adjustment for the ) or with arte-P p .012 sunate-chloroquine (OR, 9.167 [95% CI, 2.541-33.061]; P p ; test for heterogeneity, ). Artemether-lumefantrine .001 P p .391 also had significantly lower PRRs than did these 2 latter treatments ( and ; OR not calculable because no P p .050 P p .006 patients had detectable day 3 parasitemia after treatement with artemether-lumefantrine), which were not statistically different from artesunate-amodiaquine PPRs.
Among 3-day treatments assessed in at least 2 different transmission intensity areas (excluding SMRU patients since the time trend was different from the other areas), after adjustment for year of study and initial parasite density and stratifying for treatment, the combined risk for a positive parasite smear on day 3 was highest in low-transmission settings (OR for hightransmission area, 0. , likelihood P p .003 ratio test). No relationship was found between total dose of artemisinin or artemisinin derivative received on the first day of treatment or overall and the proportion of positive patients on day 3. Heterogeneity between studies was not significant ( ) . P p .143
Derivation of a Simple In Vivo Parasitological Definition of Susceptibility to Artemisinins
Additional analysis was restricted to patients who received artemisinin-derivative regimens currently recommended by the WHO for 3 days or longer (ie, studies with artesunate, artemether, or dihydroartemisinin). Because parasite clearance times increased significantly in the SMRU studies after 2001, only patients from SMRU studies treated before 2001 were included in this analysis.
Among patients with admission parasite densities between 10,000 and 100,000 parasites/mL treated for at least 3 days with artemisinin derivatives, only 1.2% (53/4535; 95% CI, 0.7%Ϫ1.6%) had detectable parasitemia on day 3-1.7% (14/ 830; 95% CI, 0.7%Ϫ2.7%) in low-transmission areas, 1.5% (13/ 863; 95% CI, 0.3%-2.7%) in moderate-transmission areas, 1.2% (14/1152; 95% CI, 0.2%-2.3%) in high-transmission areas, and 0.7% (12/1690; 95% CI, 0.3%-1.1%) in studies conducted by the SMRU before 2001.
Using the highest value of the upper 95% CI bound (∼3%) in patients with parasite densities of !100,000 parasites/mL, the probability of observing 7 or more patients with positive day 3 parasitemia in a clinical trial of 100 patients with parasite densities of !100,000 parasites/mL would be 0.03. For sample sizes of !12, no patients should have positive day 3 parasitemia ( ) if P ! .05 the true positivity rate on day 3 is р3%. (Figure 3) .
For a true positivity rate of !3%, a simple method to calculate the maximum number of patients with positive day 3 parasitemias for studies with у50 patients is the following: the number of patients with positive day 3 parasitemias (n) should not exceed . (n + 60)/24 Among 48 study arms with WHO-recommended treatments (excluding SMRU studies) and including only patients with enrollment parasite counts between 10,000 and 100,000 parasites/mL, 2 had 95% CI lower limits for day 3 PPRs of 13%. Both were relatively ineffective regimens-artesunate-chloroquine in a high-transmission area, and artesunate and sulfadoxine-pyrimethamine in a low-transmission area.
DISCUSSION
Parasite clearance can be analyzed in a number of different ways, depending in part on the frequency with which parasite densities are measured. If blood smears are done frequently enough, as in some research studies, clearance can be assessed as a continuous variable (ie, the continuous relationship between log parasite density and time). Alternatively, the proportion of patients who remain parasite positive (taken as a parasite density of у50 parasites/mL) at different time points can be assessed. The latter is simpler and therefore more suitable for routine monitoring. In the majority of clinical trials and in clinical practice, parasite densities are measured once daily or less.
Acceleration of parasite clearance is the pharmacodynamic hallmark of the artemisinin derivatives [18] . It results from the killing of circulating ring-stage parasites before they cytoadhere and their subsequent removal by the spleen [23] [24] [25] . The other antimalarial drugs have relatively little or no effects on these young circulating parasites [26, 27] and do not prevent cytoadherence in Plasmodium falciparum infections [28] . The rate of parasite clearance can therefore be used as a measure of the artemisinin pharmacodynamic effect in vivo [19] . Artemisinin resistance is characterized by prolongation in parasite clearance times [14] . The parasite clearance time is the interval from the start of treatment to the time at which parasite densities fall below the lower limit of detection by light microscopy, which corresponds to a residuum of ∼100,000,000 parasites in the body of an adult [29] . Because parasite clearance after artemisinin treatment is rapid, most patients have cleared their peripheral parasitemia by day 3 (∼72 h) after the start of treatment. Those few with persistent parasitemia represent a composite of those with the highest starting densities and the tail of a distribution of clearance rates. Artemisinin resistance is therefore associated with an increase in this proportion [14] . In the present very large series, !5% of patients with pretreatment densities of !100,000 parasites/mL had detectable parasitemias on day 3, compared with 25% of patients with parasitemia levels of 14% (corresponding to 1100,000 parasites/ mL). Thus, clearance time needs to be adjusted for the starting parasite density. With this caveat, the proportion of patients with positive blood smear results on day 3 can be used as a simple measure of artemisinin susceptibility in vivo.
It had been assumed previously that the partner drug would have a negligible effect on parasite clearance after administration of ACT, but the slower responses in patients receiving artesunate-chloroquine than other 3-day ACT regimens with a similar dose of artesunate, as well as the generally more rapid clearance with more effective ACTs (artesunate-mefloquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine), suggests that a significant contribution is made by the partner drug. The significantly higher day 3 positivity rates with 2 mg/ kg/day artesunate, artemether, or artemisinin monotherapy regimens further supports the notion that the ACT partner drug contributes to parasite clearance, although 2 mg/kg may not provide maximal ring-stage parasite killing in all patients. The importance of providing more than a single dose of an artemisinin derivative is emphasized by the slower parasite clearance with 1-day regimens.
Immunity contributes to the antimalarial therapeutic response. Although differences were small, parasite clearance was slowest in the low-transmission settings and most rapid in hightransmission settings even with relatively ineffective partner drugs, suggesting that the splenic clearance process for the killed ring-stage parasites may be enhanced. Splenomegaly per se was not associated with accelerated parasite clearance, but splenic structural reorganization and activation in high-transmission areas together with antibody production may enhance clearance function in acute infections. The day 3 parasite count proved a useful predictor of therapeutic response. Previous studies with monotherapies have shown the value of prolonged parasite clearance in predicting subsequent recrudescence. With mefloquine treatment, persistence of parasitemia to day 4 proved to be the best determinant of treatment failure [30] . Slow parasite clearance reflects a reduced contribution of the artemisinin component of an ACT to overall parasite killing, leaving a larger biomass for the partner drug to remove [29] .
Recent data from the Thai-Cambodian border suggest that artemisinin resistance in P. falciparum malaria has developed there [2, 13] . This may be a multistage process. It is imperative to determine whether resistance has spread beyond this region or emerged independently elsewhere. The day 3 parasite count is a simple measure that can be followed routinely in in vivo monitoring studies. In a clinical study of n patients presenting with parasite densities of !100,000 parasites/mL, if the number who still have parasitemia on day 3 (72 h) after the start of treatment with ACT exceeds , then additional, more (n + 60)/24 detailed investigations may be warranted.
